Head to Head Comparison: Cerus (NASDAQ:CERS) & Glucose Health (OTCMKTS:GLUC)

Cerus (NASDAQ:CERS) and Glucose Health (OTCMKTS:GLUC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.

Volatility & Risk

Cerus has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500. Comparatively, Glucose Health has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Cerus and Glucose Health, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	0	0	2	0	3.00
Glucose Health	0	0	0	0	0.00

Cerus currently has a consensus target price of $3.50, indicating a potential upside of 143.06%. Given Cerus’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Cerus is more favorable than Glucose Health.

Profitability

This table compares Cerus and Glucose Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cerus	-9.81%	-33.77%	-9.32%
Glucose Health	-82.29%	N/A	N/A

Institutional & Insider Ownership

78.4% of Cerus shares are owned by institutional investors. 5.6% of Cerus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Cerus and Glucose Health”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$192.51 million	1.43	-$20.92 million	($0.10)	-14.40
Glucose Health	$380,000.00	4.25	-$320,000.00	($0.03)	-3.09

Glucose Health has lower revenue, but higher earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Glucose Health, indicating that it is currently the more affordable of the two stocks.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

About Glucose Health

Glucose Health, Inc. engages in the formulation, manufacturing, marketing, and distribution of soluble fiber infused nutritional beverages. It offers soluble fiber infused powdered iced tea, and flavored drink mixes for pre-diabetic and diabetic persons under the GLUCODOWN brand in North America. The company was formerly known as Bio-Solutions Corp. and changed its name to Glucose Health, Inc. in November 2014. Glucose Health, Inc. was incorporated in 2007 and is based in Bentonville, Arkansas.